Loading clinical trials...
Loading clinical trials...
Front-line Venetoclax and Obinutuzumab Combination Followed by Venetoclax or Venetoclax and Zanubrutinib Combination in Patients With Residual Disease: a Minimal Residual Disease (MRD) Tailored Treatment for Young Patients With High-risk CLL
Conditions
Interventions
VenObi+Ven or VenObi+VenZan
Locations
8
Italy
Ematologia AOU Careggi
Florence, Italy
Ematologia IRST D.Amadori
Meldola, Italy
Ematologia AO di Perugia
Perugia, Italy
Ematologia Ospedale S.M. delle Croci
Ravenna, Italy
Ematologia Ospedale Infermi
Rimini, Italy
Ematologia Policlinico Gemelli
Roma, Italy
Start Date
July 21, 2023
Primary Completion Date
May 1, 2026
Completion Date
July 1, 2027
Last Updated
March 17, 2026
NCT06846671
NCT07218341
NCT07030400
NCT07277231
NCT05006716
NCT06859424
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions